Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) in Patients With Selected Advanced Solid Tumors

Trial Profile

A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) in Patients With Selected Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2019

At a glance

  • Drugs Camidanlumab tesirine (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors ADC Therapeutics
  • Most Recent Events

    • 04 Jan 2019 According to an ADC Therapeutics media release, the first patient has been dosed in this study.
    • 14 Nov 2018 Status changed from not yet recruiting to recruiting.
    • 08 Nov 2018 According to an ADC Therapeutics media release, the company plans to initiate phase Ib portion of the trial
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top